Bortezomib-Kimia

• Targeted mechanism that selectively inhibits the BCR-ABL tyrosine kinase to disrupt signaling pathways driving abnormal cell growth in chronic myelogenous leukemia and gastrointestinal stromal tumors (first-line). • Clinically established with robust trials confirming its ability to control disease pro...

• Used for non-small cell lung cancer (NSCLC) as first-line therapy. Targets EGFR mutations to inhibit tumor growth. •  An EGFR tyrosine kinase inhibition which interrupts receptor signaling to limit tumor cell proliferation. • Robust clinical studies confirm benefits in non-small cell lung and pan...

• Inhibits multiple receptor tyrosine kinases, including VEGF, PDGF, and c-kit, to reduce tumor angiogenesis and growth. • Demonstrated clinical effectiveness in advanced renal cell carcinoma (second-line) and soft tissue sarcoma (second-line) through robust trials. • Administered orally, offering ...

• Multi-targeted tyrosine kinase inhibitor that blocks VEGF and PDGF receptors to hinder tumor angiogenesis and cell proliferation • Proven efficacy in advanced renal cell carcinoma (second-line), gastrointestinal stromal tumors (first-line), and pancreatic neuroendocrine tumors (second-line) • Administ...

• Fampridine acts by blocking voltage-dependent potassium channels, thereby enhancing conduction in demyelinated nerve fibers. • Robust clinical trials have confirmed its ability to improve walking speed and overall mobility in multiple sclerosis patients. • Delivered in tablet form, ensuring convenient...

• Incorporates into nucleic acids to induce DNA hypomethylation. • Clinically validated for myelodysplastic syndromes and AML. • Flexible administration via subcutaneous injection or IV infusion. • Established safety profile confirmed in rigorous clinical trials. • Demonstrated improvements in surviva...

• Supports DNA synthesis and repair while mitigating methotrexate toxicity. • Proven efficacy in enhancing fluorouracil therapy for colorectal cancer and serving as methotrexate rescue. • Enhances chemotherapeutic regimens to optimize patient outcomes. • Demonstrated tolerability and manageable adverse...

• Disrupts tumor DNA through crosslink formation to impede cell replication. • Widely validated in the treatment of various solid malignancies, including ovarian and lung cancers. • Administered via infusion to integrate seamlessly into contemporary oncology protocols. • Exhibits manageable adverse eff...

• Facilitates DNA crosslinking to inhibit replication and promote cancer cell apoptosis. • Demonstrates robust efficacy in various solid tumors, including testicular, ovarian, and bladder cancers. • Delivered via infusion, aligning with established oncology treatment protocols. • Often paired with othe...

• A potent taxane agent which stabilizes microtubules to disrupt cell division and promote apoptosis in malignant cells. • Demonstrated efficacy across various cancers including breast, lung, and prostate. • Seamlessly integrated into standard oncology treatment protocols. • Adverse effects are managea...

• An anthracycline mechanism which intercalates into DNA and inhibits topoisomerase II, promoting the generation of free radicals that induce tumor cell death. • Demonstrates a longstanding, evidence-based role in treating breast cancer, lymphomas, sarcomas, and other malignancies. • Delivered via IV in...

• An anthracycline derivative which intercalates into DNA and inhibits topoisomerase II, disrupting cancer cell replication. • Demonstrated success in the treatment of breast and other solid tumors through extensive clinical trials. • Delivered via infusion, integrating smoothly into established chemoth...